7 OVERVIEW
7 Latest key takeaways
9 DISEASE BACKGROUND
9 Migraine without aura
9 Migraine with aura
10 TREATMENT
10 Analgesics
10 NSAIDs
10 Serotonergic drugs
11 CGRP inhibitors
11 Prophylactic agents for migraine
12 EPIDEMIOLOGY
12 Prevalence methodology
16 MARKETED DRUGS
22 PIPELINE DRUGS
31 KEY REGULATORY EVENTS
31 Cefaly Touts First OTC Dual-Purpose eTNS Migraine Device
31 Cipla Gets CGT Nod For US Migranal Rival
31 Biohaven Goes All In On ODT With Nurtec
32 Dr Reddy's Elyxyb Receives US Approval For Its NDA
32 FDA Issues Response Letter For Rizaport
32 Relief For Migraine as England's NICE Reverses Ajovy Knockback
32 Yes For Shionogi But No For Lilly In Latest EMA Recommendations
33 Biohaven's Oral CGRP Inhibitor Nurtec ODT Approved In The US For Acute Migraine
33 Pricing Could Help Lundbeck's Vyepti In Slow-Growing CGRP Market
33 Triptan Switches Offer Hope For Australia's OTC Market
33 Allergan's Oral CGRP Inhibitor Ubrelvy Approved For Migraine Attacks
34 Lilly Expands Migraine Franchise With Reyvow Approval
34 IntelGenx Takes A Fourth Try At Rizaport Approval
35 PROBABILITY OF SUCCESS
36 LICENSING AND ASSET ACQUISITION DEALS
36 Biohaven secures up to $450m deal with Royalty Pharma
36 Currax Gains NA License To Optinose's Onzetra Xsail Migraine Treatment
36 Deals Shaping The Medical Industry, October 2019
37 CLINICAL TRIAL LANDSCAPE
38 Sponsors by status
39 Sponsors by phase
40 Recent events
42 DRUG ASSESSMENT MODEL
42 Acute migraine
43 Chronic and episodic migraine prevention
46 MARKET DYNAMICS
48 FUTURE TRENDS
48 Brand awareness among HCPs will contribute to growth
48 Oral CGRPs for migraine prophylaxis have the greatest commercial potential
50 CONSENSUS FORECASTS
52 RECENT EVENTS AND ANALYST OPINION
52 Qtrypta for Migraine (October 21, 2020)
52 Qtrypta for Migraine (September 30, 2020)
53 Reyvow for Migraine (September 11, 2020)
55 STS101 for Migraine (September 10, 2020)
57 Atogepant for Migraine (July 29, 2020)
59 INP-104 for Migraine (June 10, 2020)
61 AXS-07 for Migraine (April 6, 2020)
63 Nurtec ODT for Migraine (March 30, 2020)
65 AXS-07 for Migraine (December 30, 2019)
67 Zavegepant for Migraine (December 17, 2019)
69 KEY UPCOMING EVENTS
70 UNMET NEEDS
71 BIBLIOGRAPHY
71 Prescription information
73 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in prevalent cases of migraine, 2019-28
22 Figure 2: Overview of pipeline drugs for migraine in the US
23 Figure 3: Pipeline drugs for migraine, by company
23 Figure 4: Pipeline drugs for migraine, by drug type
23 Figure 5: Pipeline drugs for migraine, by classification
35 Figure 6: Probability of success in the migraine pipeline
37 Figure 7: Clinical trials in migraine
37 Figure 8: Top 10 drugs for clinical trials in migraine
38 Figure 9: Top 10 companies for clinical trials in migraine
38 Figure 10: Trial locations in migraine
39 Figure 11: Migraine trials status
40 Figure 12: Migraine trials sponsors, by phase
42 Figure 13: Datamonitor Healthcare's drug assessment summary for migraine
46 Figure 14: Market dynamics in migraine (1 of 2)
47 Figure 15: Market dynamics in migraine (2 of 2)
48 Figure 16: Future trends in migraine
55 Figure 17: Reyvow for Migraine (September 11, 2020): Phase III - CENTURION (>4 Migraine Attacks)
57 Figure 18: STS101 for Migraine (September 10, 2020): Phase III - EMERGE
59 Figure 19: Atogepant for Migraine (July 29, 2020): Phase III - ADVANCE
61 Figure 20: INP-104 for Migraine (June 10, 2020): Phase III - STOP-301
63 Figure 21: AXS-07 for Migraine (April 6, 2020): Phase III - INTERCEPT (Early)
65 Figure 22: Nurtec ODT for Migraine (March 30, 2020): Phase II/III - BHV3000-305 (Migraine Prevention)
67 Figure 23: AXS-07 for Migraine (December 30, 2019): Phase III - MOMENTUM (Acute)
68 Figure 24: Zavegepant for Migraine (December 17, 2019): Phase II/III - 201
69 Figure 25: Key upcoming events in migraine
LIST OF TABLES
13 Table 1: Prevalent cases of migraine, 2019-28
15 Table 2: Prevalence proportions of migraine, 2019-28
17 Table 3: Marketed drugs for migraine
25 Table 4: Pipeline drugs for migraine in the US
50 Table 5: Historical global sales, by drug ($m), 2015-19
51 Table 6: Forecasted global sales, by drug ($m), 2020-24
52 Table 7: Qtrypta for Migraine (October 21, 2020)
53 Table 8: Qtrypta for Migraine (September 30, 2020)
54 Table 9: Reyvow for Migraine (September 11, 2020)
56 Table 10: STS101 for Migraine (September 10, 2020)
58 Table 11: Atogepant for Migraine (July 29, 2020)
60 Table 12: INP-104 for Migraine (June 10, 2020)
62 Table 13: AXS-07 for Migraine (April 6, 2020)
64 Table 14: Nurtec ODT for Migraine (March 30, 2020)
65 Table 15: AXS-07 for Migraine (December 30, 2019)
67 Table 16: Zavegepant for Migraine (December 17, 2019)